Fibrous capsule-resistant, controllably degradable and functionalizable zwitterion-albumin hybrid hydrogels
Source abstract
Abstract
Foreign body response (FBR) represents an immune-mediated cascade reaction capable of inducing the rejection of foreign implants, thereby compromising their in vivo performance. Pure zwitterionic hydrogels have demonstrated the ability to resist long-term FBR, owing to their outstanding antifouling capabilities. However, achieving such a robust anti-FBR effect necessitates stringent requirements concerning the purity of zwitterionic materials, which constrains their broader functional applications. Herein, we present a biocompatible, controllably degradable, and functionalizable zwitterion-albumin hybrid hydrogel. The zwitterionic hydrogel crosslinked with serum albumin exhibits controllable degradation and excels in preventing the adsorption of various proteins and adhesion of cells and bacteria. Moreover, the hydrogel significantly alleviates the host's FBR compared with PEG hydrogels and particularly outperforms PEG-based cross-linker crosslinked zwitterionic hydrogels in reducing collagen encapsulation when subcutaneously implanted into mice. The zwitterion-albumin hybrid hydrogel shows potential as a functionalizable anti-FBR material in the context of implantable materials and biomedical devices.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Polymer Surface Interaction Studies · Hemostasis and retained surgical items · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
MOE Key Laboratory of Macromolecule Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, P. R. China
International Research Center for X Polymers, International Campus, Zhejiang University, Haining, P. R. China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · National Basic Research Program of China · Fundamental Research Funds for the Central Universities · Zhejiang University
References (50)
Show source-provided references
1. Beatty · Sci. Robot · 2023 · 8 · eabq482110.1126/scirobotics.abq4821 ↗
2. Kutner · Adv. Funct. Mater. · 2021 · 31 · 201092910.1002/adfm.202010929 ↗
3. Zhang · Adv. Funct. Mater. · 2020 · 31 · 200722610.1002/adfm.202007226 ↗
4. Veiseh · Adv. Drug Delivery Rev. · 2019 · 144 · 14810.1016/j.addr.2019.08.010 ↗
5. Anderson · Semin. Immunol. · 2008 · 20 · 8610.1016/j.smim.2007.11.004 ↗
6. Yang · Biomater. Sci. · 2023 · 11 · 773010.1039/D3BM00629H ↗
7. Schreib · Adv. Mater. · 2023 · 35 · 220570910.1002/adma.202205709 ↗
8. Bose · Nat. Biomed. Eng. · 2020 · 4 · 81410.1038/s41551-020-0538-5 ↗
9. Xie · Nat. Biomed. Eng. · 2018 · 2 · 89410.1038/s41551-018-0273-3 ↗
10. Vegas · Nat. Biotechnol. · 2016 · 34 · 34510.1038/nbt.3462 ↗
11. Mukherjee · Nat. Biomed. Eng. · 2023 · 7 · 86710.1038/s41551-023-01016-2 ↗
12. Liu · Nat. Commun. · 2019 · 10 · 526210.1038/s41467-019-13238-7 ↗
13. Bochenek · Nat. Biomed. Eng. · 2018 · 2 · 81010.1038/s41551-018-0275-1 ↗
14. Vegas · Nat. Med. · 2016 · 22 · 30610.1038/nm.4030 ↗
15. Yan · Adv. Funct. Mater. · 2019 · 29 · 190258110.1002/adfm.201902581 ↗
16. Liu · Adv. Mater. · 2021 · 33 · 210285210.1002/adma.202102852 ↗
17. Liu · Adv. Mater. · 2021 · 33 · 210285210.1002/adma.202102852 ↗
18. Wang · Sci. Adv. · 2021 · 7 · eabd583510.1126/sciadv.abd5835 ↗
19. Chang · J. Am. Chem. Soc. · 2022 · 144 · 1214710.1021/jacs.2c02677 ↗
20. Zhang · Nat. Commun. · 2021 · 12 · 110.1038/s41467-020-20314-w ↗
21. Zhang · Angew. Chem., Int. Ed. · 2020 · 59 · 958610.1002/anie.202000416 ↗
22. Farah · Nat. Mater. · 2019 · 18 · 89210.1038/s41563-019-0377-5 ↗
23. Dong · Sci. Adv. · 2021 · 7 · eabc544210.1126/sciadv.abc5442 ↗
24. Zhang · Nat. Biotechnol. · 2013 · 31 · 55310.1038/nbt.2580 ↗
25. Chung · Biomater. Sci. · 2023 · 11 · 482710.1039/D2BM01960D ↗
26. Li · Chem. Rev. · 2022 · 122 · 1707310.1021/acs.chemrev.2c00344 ↗
27. Kim · J. Mater. Chem. B · 2016 · 4 · 160010.1039/C5TB01605C ↗
28. Zhang · J. Biomater. Sci., Polym. Ed. · 2009 · 20 · 184510.1163/156856208X386444 ↗
29. Jansen · Biomacromolecules · 2018 · 19 · 288010.1021/acs.biomac.8b00444 ↗
30. Zhang · Nat. Biomed. Eng. · 202310.1038/s41551-023-01108-z ↗
31. Larsen · Mol. Cell. Ther. · 2016 · 4 · 110.1186/s40591-016-0048-8 ↗
32. Elsadek · J. Controlled Release · 2012 · 157 · 410.1016/j.jconrel.2011.09.069 ↗
33. Sleep · Expert Opin. Drug Delivery · 2015 · 12 · 79310.1517/17425247.2015.993313 ↗
34. Ling · Adv. Funct. Mater. · 2023 · 33 · 221334210.1002/adfm.202213342 ↗
35. Zhang · Nat. Commun. · 2021 · 12 · 532710.1038/s41467-021-25581-9 ↗
36. Tang · Adv. Funct. Mater. · 2021 · 31 · 210132010.1002/adfm.202101320 ↗
37. Li · Nanomaterials · 2022 · 12 · 243910.3390/nano12142439 ↗
38. Tao · J. Mater. Chem. B · 2020 · 8 · 608010.1039/D0TB01111H ↗
39. Merlot · Front. Physiol. · 2014 · 5 · 29910.3389/fphys.2014.00299 ↗
40. Larsen · Mol. Cell. Ther. · 2016 · 4 · 310.1186/s40591-016-0048-8 ↗
41. Elsadek · J. Controlled Release · 2012 · 157 · 410.1016/j.jconrel.2011.09.069 ↗
42. An · Theranostics · 2017 · 7 · 366710.7150/thno.19365 ↗
43. Zhang · Biomacromolecules · 2008 · 9 · 268610.1021/bm800407r ↗
44. Habeeb · Anal. Biochem. · 1966 · 14 · 32810.1016/0003-2697(66)90275-2 ↗
45. Noskovicova · Nat. Biomed. Eng. · 2021 · 5 · 143710.1038/s41551-021-00722-z ↗
46. Scott · Acta Biomater. · 2021 · 122 · 22010.1016/j.actbio.2020.12.040 ↗
47. Blakney · J. Biomed. Mater. Res., Part A · 2012 · 100A · 137510.1002/jbm.a.34104 ↗
48. Mi · Angew. Chem., Int. Ed. · 2014 · 53 · 174610.1002/anie.201304060 ↗
49. Ong · Biotechnol. Bioeng. · 2019 · 116 · 345710.1002/bit.27167 ↗
50. Doloff · Nat. Mater. · 2017 · 16 · 67110.1038/nmat4866 ↗